oral TRPA1 ion-channel inhibitor
for asthma, target engagement in HV Ph. I
from ligand-based design, cryo-EM structure
J. Exp. Med., Apr. 5, 2021
Genentech Inc., South San Francisco, CA
GDC-0334
The Genentech TRPA1 ion-channel inhibitor, GDC-0334, is an oral candidate for asthma that demonstrated target engagement in a non-invasive skin- based Ph. I study. It reduces TRPA1 agonist-induced symptoms in…